Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
5.86
-0.09 (-1.51%)
Jul 8, 2025, 11:31 AM - Market open
Trevi Therapeutics Employees
Trevi Therapeutics had 26 employees as of December 31, 2024. The number of employees increased by 1 or 4.00% compared to the previous year.
Employees
26
Change (1Y)
1
Growth (1Y)
4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,821,115
Market Cap
698.19M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
TRVI News
- 7 days ago - Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism - PRNewsWire
- 4 weeks ago - Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - PRNewsWire
- 4 weeks ago - Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - PRNewsWire
- 5 weeks ago - Trevi Therapeutics Announces Proposed Public Offering of Common Stock - PRNewsWire
- 5 weeks ago - Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients - Benzinga
- 5 weeks ago - Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough - PRNewsWire
- 5 weeks ago - Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough - PRNewsWire
- 5 weeks ago - Trevi Therapeutics to Participate in Upcoming June Conferences - PRNewsWire